Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.66 |
| ▸ | GSK3B | P49841 | 2/20 | 0.66 |
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5421482 | 0.98 | PTPN1 (0.63) | PTPN1GSK3BCES2CES1MMP1 | |
| SCHEMBL30357692 | 0.87 | PTPN1 (0.51) | PTPN1GSK3BCES2CES1MMP1 | |
| SCHEMBL8085399 | 0.85 | GSK3B (0.54) | PTPN1GSK3BCES2CES1MMP1 | |
| SCHEMBL26135918 | 0.83 | MMP1 (0.76) | PTPN1GSK3BCES2CES1MMP1 | |
| SCHEMBL29987081 | 0.83 | PTPN1 (0.75) | PTPN1GSK3BCES2CES1MMP1 | |
| SCHEMBL1360049 | 0.81 | PTPN1 (0.68) | PTPN1GSK3BCES2CES1MMP1 | |
| SCHEMBL2074662 | 0.81 | PTPN1 (0.68) | PTPN1GSK3BCES2CES1MMP1 | |
| SCHEMBL3569892 | 0.80 | PTPN1 (0.66) | PTPN1GSK3BCES2CES1MMP1 | |
| Hydrochloric Acid SCHEMBL13738814 | 0.79 | GSK3B (0.42) | PTPN1GSK3BCES1HDAC1HDAC8 | |
| SCHEMBL3102483 | 0.79 | GSK3B (0.66) | PTPN1GSK3BCES2CES1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| CN-116514790-A | Tri-aromatic heterocyclic piperazine small molecular organic compound targeting STAT3 and application thereof | 华东师范大学 | 2023-08-01 | — | — | CN | disclosed |
| CN-116157394-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-4021441-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | Trustees of Dartmouth College (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021042046-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2021-03-04 | — | — | WO | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | INDIVIOR UK LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| WO-2017064488-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LIMITED (GB) | 2017-04-20 | — | — | WO | disclosed |
| EP-2004595-A1 | N-PHENYL-1,1,1-TRIFLUOROMETHANESULFONAMIDE HYDRAZONE DERIVATIVE COMPOUNDS AND THEIR USAGE IN CONTROLLING PARASITES | Schering-Plough Ltd. (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007116314-A1 | N-PHENYL-1,1,1-TRIFLUOROMETHANESULFONAMIDE HYDRAZONE DERIVATIVE COMPOUNDS AND THEIR USAGE IN CONTROLLING PARASITES | SCHERING-PLOUGH LTD. (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-0379145-B1 | Substituted quinolinecarboxylic acids | AMERICAN CYANAMID CO (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0653421-B1 | Process for preparing 2-cyanoimidazole compounds | ISHIHARA SANGYO KAISHA (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5552557-A | Process for preparing 2-cyanoimidazole compounds by reaction of an amino ketone compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1996-09-03 | — | — | US | disclosed |
| EP-0653421-A1 | Process for preparing 2-cyanoimidazole compounds | ISHIHARA SANGYO KAISHA LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
| US-5214059-A | Dermatitis, psoriasis | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-05-25 | — | — | US | disclosed |
| US-5166170-A | 2-(AMINOARYL) INDOLES AND INDOLINES AS TOPICAL ANTIINFLAMMATORY AGENTS FOR THE TREATMENT OF SKIN DISORDERS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-11-24 | — | — | US | disclosed |
| EP-0406734-A2 | 2-(Aminoaryl)indoles and indolines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-01-09 | — | — | EP | disclosed |
| US-4968702-A | ANTIARTHRITIC, INHIBITORS OF PROGRESSIVE JOINT DETERIORATION, IMMUNOSUPPRESSANT | AMERICAN CYANAMID COMPANY (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0379145-A2 | Substituted quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-25 | — | — | EP | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | DRD3, DRD2, SLC6A3 | PTPN1 1167/4885GSK3B 1218/4885CES2 736/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | PTPN1 1425/4885GSK3B 487/4885CES2 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.